Davita Inc (NYSE:DVA) – Investment analysts at KeyCorp decreased their FY2017 earnings estimates for shares of Davita in a report issued on Wednesday. KeyCorp analyst J. Gurda now forecasts that the company will earn $3.53 per share for the year, down from their prior estimate of $3.58.
Several other brokerages have also weighed in on DVA. Zacks Investment Research upgraded shares of Davita from a “hold” rating to a “buy” rating and set a $77.00 target price on the stock in a research report on Tuesday, April 18th. TheStreet upgraded shares of Davita from a “c+” rating to a “b-” rating in a research report on Monday, April 3rd. Finally, Royal Bank of Canada restated a “hold” rating and set a $62.00 target price on shares of Davita in a research report on Friday, February 17th. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $70.33.
COPYRIGHT VIOLATION NOTICE: “KeyCorp Weighs in on Davita Inc’s FY2017 Earnings (DVA)” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/05/20/keycorp-weighs-in-on-davita-incs-fy2017-earnings-dva-updated.html.
Davita (NYSE:DVA) traded up 0.61% during midday trading on Monday, reaching $66.27. The company had a trading volume of 294,153 shares. The stock has a market capitalization of $12.90 billion, a PE ratio of 10.88 and a beta of 1.02. The firm’s 50 day moving average is $67.59 and its 200 day moving average is $65.00. Davita has a 1-year low of $54.50 and a 1-year high of $78.77.
Davita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, May 2nd. The company reported $0.79 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.82 by $0.03. Davita had a return on equity of 16.16% and a net margin of 4.92%. The firm had revenue of $3.70 billion during the quarter, compared to analyst estimates of $3.69 billion.
In related news, Director William L. Roper sold 12,994 shares of the firm’s stock in a transaction that occurred on Thursday, May 4th. The shares were sold at an average price of $65.89, for a total transaction of $856,174.66. Following the sale, the director now owns 45,277 shares in the company, valued at $2,983,301.53. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.10% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the company. SRS Capital Advisors Inc. purchased a new stake in shares of Davita during the fourth quarter worth about $118,000. Raymond James Trust N.A. bought a new position in Davita during the first quarter worth $202,000. Seven Bridges Advisors LLC increased its position in Davita by 187.1% in the third quarter. Seven Bridges Advisors LLC now owns 3,066 shares of the company’s stock worth $203,000 after buying an additional 1,998 shares in the last quarter. Acrospire Investment Management LLC increased its position in Davita by 166.7% in the third quarter. Acrospire Investment Management LLC now owns 3,200 shares of the company’s stock worth $211,000 after buying an additional 2,000 shares in the last quarter. Finally, Advisor Partners LLC bought a new position in Davita during the first quarter worth $218,000. Hedge funds and other institutional investors own 85.31% of the company’s stock.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita Inc and related companies with MarketBeat.com's FREE daily email newsletter.